PMID- 30587053
OWN - NLM
STAT- MEDLINE
DCOM- 20200525
LR  - 20200525
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 15
IP  - 4
DP  - 2019 Apr
TI  - Topical agents for the treatment of atopic dermatitis.
PG  - 369-382
LID - 10.1080/1744666X.2019.1564038 [doi]
AB  - Atopic dermatitis (AD) is perhaps the most common inflammatory skin disorder 
      worldwide, with an increasing incidence in developed countries. The mainstay 
      treatment for patients with AD is topical therapies, which are used not only by 
      the mild patients but also by the moderate-to-severe patients, in conjunction 
      with systemic treatment. While topical steroids and calcineurin antagonists are 
      widely used, these are associated with long-term cutaneous adverse effects (AEs) 
      or a black box warning, preventing their chronic use. Areas covered: The aim of 
      this review is to provide a comprehensive overview of new and upcoming topical 
      therapies currently in development and undergoing clinical trials, as well as 
      their safety and efficacy profiles, and discuss current topicals used in the 
      management of AD. Expert opinion: AD is a heterogeneous disease with complex 
      pathophysiology. Treatments available to date for AD provide disease control; 
      however, patients struggle to find an optimized therapeutic regimen they may use 
      long term and without severe effects. Novel therapies are currently under 
      investigation, with the hope of shifting the paradigm of AD management from 
      symptom control to disease eradication.
FAU - Diaz, Aisleen
AU  - Diaz A
AD  - a Department of Dermatology , Icahn School of Medicine , New York , NY , USA.
AD  - b Laboratory for Inflammatory Skin Diseases , New York , NY , USA.
AD  - c Ponce Health Sciences University School of Medicine , Ponce , PR , USA.
FAU - Guttman-Yassky, Emma
AU  - Guttman-Yassky E
AD  - a Department of Dermatology , Icahn School of Medicine , New York , NY , USA.
AD  - b Laboratory for Inflammatory Skin Diseases , New York , NY , USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190108
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Calcineurin Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Administration, Topical
MH  - Animals
MH  - Calcineurin Inhibitors/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Dermatitis, Atopic/*drug therapy
MH  - Expert Testimony
MH  - Humans
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Skin/drug effects/*pathology
MH  - Tacrolimus/*therapeutic use
OTO - NOTNLM
OT  - Atopic dermatitis
OT  - crisaborole
OT  - tapinarof
OT  - topical calcineurin inhibitors
OT  - topical corticosteroids
OT  - topical janus kinase inhibitors
OT  - topical phosphodiaesterase-4 inhibitors
EDAT- 2018/12/28 06:00
MHDA- 2020/05/26 06:00
CRDT- 2018/12/28 06:00
PHST- 2018/12/28 06:00 [pubmed]
PHST- 2020/05/26 06:00 [medline]
PHST- 2018/12/28 06:00 [entrez]
AID - 10.1080/1744666X.2019.1564038 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2019 Apr;15(4):369-382. doi: 
      10.1080/1744666X.2019.1564038. Epub 2019 Jan 8.